nach oben

Arthritis Research & Therapy

Erschienen in:

01.02.2009 | Review

Hypoxia. Regulation of NFκB signalling during inflammation: the role of hydroxylases

verfasst von: Kathryn M Oliver, Cormac T Taylor, Eoin P Cummins

Erschienen in: Arthritis Research & Therapy | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

NFκB is a master regulator of innate immunity and inflammatory signalling. Microenvironmental hypoxia has long been identified as being coincident with chronic inflammation. The contribution of microenvironmental hypoxia to NFκB-induced inflammation has more recently been appreciated. Identification of the co-regulation of NFκB and hypoxia inducible factor (HIF) pathways by 2-oxo-glutarate-dependent hydroxylase family members has highlighted an intimate relationship between NFκB inflammatory signalling and HIF-mediated hypoxic signalling pathways. Adding another layer of complexity to our understanding of the role of NFκB inflammatory signalling by hypoxia is the recent recognition of the contribution of basal NFκB activity to HIF-1α transcription. This observation implicates an important and previously unappreciated role for NFκB in inflammatory disease where HIF-1α is activated. The present review will discuss recent literature pertaining to the regulation of NFκB inflammatory signalling by hypoxia and some of the inflammatory diseases where this may play an important role. Furthermore, we will discuss the potential for prolylhydroxylase inhibitors in inflammatory disease.

Nur mit Berechtigung zugänglich

Chen LF, Greene WC: Shaping the nuclear action of NF-κB. Nat Rev Mol Cell Biol. 2004, 5: 392-401. 10.1038/nrm1368.CrossRefPubMed

Hayden MS, Ghosh S: Shared principles in NF-κB signaling. Cell. 2008, 132: 344-362. 10.1016/j.cell.2008.01.020.CrossRefPubMed

Karin M: The IκB kinase – a bridge between inflammation and cancer. Cell Res. 2008, 18: 334-342. 10.1038/cr.2008.30.CrossRefPubMed

Ryseck RP, Bull P, Takamiya M, Bours V, Siebenlist U, Dobrzanski P, Bravo R: RelB, a new Rel family transcription activator that can interact with p50-NF-κB. Mol Cell Biol. 1992, 12: 674-684.PubMedCentralCrossRefPubMed

Chen YQ, Sengchanthalangsy LL, Hackett A, Ghosh G: NF-κB p65 (RelA) homodimer uses distinct mechanisms to recognize DNA targets. Structure. 2000, 8: 419-428. 10.1016/S0969-2126(00)00123-4.CrossRefPubMed

Van Waes C, Yu M, Nottingham L, Karin M: Inhibitor-κB kinase in tumor promotion and suppression during progression of squamous cell carcinoma. Clin Cancer Res. 2007, 13: 4956-4959. 10.1158/1078-0432.CCR-07-1287.CrossRefPubMed

Chen ZJ, Parent L, Maniatis T: Site-specific phosphorylation of IκBα by a novel ubiquitination-dependent protein kinase activity. Cell. 1996, 84: 853-862. 10.1016/S0092-8674(00)81064-8.CrossRefPubMed

Chen FE, Huang DB, Chen YQ, Ghosh G: Crystal structure of p50/p65 heterodimer of transcription factor NF-κB bound to DNA. Nature. 1998, 391: 410-413. 10.1038/34356.CrossRefPubMed

Pahl HL: Activators and target genes of Rel/NF-κB transcription factors. Oncogene. 1999, 18: 6853-6866. 10.1038/sj.onc.1203239.CrossRefPubMed

10.

Moynagh PN: The NF-κB pathway. J Cell Sci. 2005, 118 (Pt 20): 4589-4592. 10.1242/jcs.02579.CrossRefPubMed

11.

Cummins EP, Berra E, Comerford KM, Fitzgerald KT, Seeballuck F, Godson C, Nielsen JE, Moynagh P, Pouyssegur J, Taylor CT: Prolyl hydroxylase-1 negatively regulates IkB kinase-β giving insight into hypoxia-induced NFkB activity. Proc Natl Acad Sci USA. 2006, 103: 18154-18159. 10.1073/pnas.0602235103.PubMedCentralCrossRefPubMed

12.

Koong AC, Chen EY, Giaccia AJ: Hypoxia causes the activation of nuclear factor κB through the phosphorylation of IκBα on tyrosine residues. Cancer Res. 1994, 54: 1425-1430.PubMed

13.

Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, Johnson RS, Haddad GG, Karin M: NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α. Nature. 2008, 453: 807-811. 10.1038/nature06905.PubMedCentralCrossRefPubMed

14.

Li N, Karin M: Ionizing radiation and short wavelength UV activate NF-κB through two distinct mechanisms. Proc Natl Acad Sci USA. 1998, 95: 13012-13017. 10.1073/pnas.95.22.13012.PubMedCentralCrossRefPubMed

15.

O'Dea EL, Kearns JD, Hoffmann A: UV as an amplifier rather than inducer of NF-κB activity. Mol Cell. 2008, 30: 632-641. 10.1016/j.molcel.2008.03.017.PubMedCentralCrossRefPubMed

16.

Schmidt KN, Amstad P, Cerutti P, Baeuerle PA: The roles of hydrogen peroxide and superoxide as messengers in the activation of transcription factor NF-κB. Chem Biol. 1995, 2: 13-22. 10.1016/1074-5521(95)90076-4.CrossRefPubMed

17.

Khachigian LM, Resnick N, Gimbrone MA, Collins T: Nuclear factor-κB interacts functionally with the platelet-derived growth factor B-chain shear-stress response element in vascular endothelial cells exposed to fluid shear stress. J Clin Invest. 1995, 96: 1169-1175. 10.1172/JCI118106.PubMedCentralCrossRefPubMed

18.

Leeper-Woodford SK, Detmer K: Acute hypoxia increases alveolar macrophage tumor necrosis factor activity and alters NF-κB expression. Am J Physiol. 1999, 276 (6 Pt 1): L909-L916.PubMed

19.

Chandel NS, Trzyna WC, McClintock DS, Schumacker PT: Role of oxidants in NF-κB activation and TNF-α gene transcription induced by hypoxia and endotoxin. J Immunol. 2000, 165: 1013-1021.CrossRefPubMed

20.

Schmedtje JF, Ji YS, Liu WL, DuBois RN, Runge MS: Hypoxia induces cyclooxygenase-2 via the NF-κB p65 transcription factor in human vascular endothelial cells. J Biol Chem. 1997, 272: 601-608. 10.1074/jbc.272.1.601.CrossRefPubMed

21.

Taylor CT, Dzus AL, Colgan SP: Autocrine regulation of epithelial permeability by hypoxia: role for polarized release of tumor necrosis factor α. Gastroenterology. 1998, 114: 657-668. 10.1016/S0016-5085(98)70579-7.CrossRefPubMed

22.

Matsui H, Ihara Y, Fujio Y, Kunisada K, Akira S, Kishimoto T, Yamauchi-Takihara K: Induction of interleukin (IL)-6 by hypoxia is mediated by nuclear factor (NF)-κB and NF-IL6 in cardiac myocytes. Cardiovasc Res. 1999, 42: 104-112. 10.1016/S0008-6363(98)00285-5.CrossRefPubMed

23.

Zampetaki A, Mitsialis SA, Pfeilschifter J, Kourembanas S: Hypoxia induces macrophage inflammatory protein-2 (MIP-2) gene expression in murine macrophages via NF-κB: the prominent role of p42/p44 and PI3 kinase pathways. FASEB J. 2004, 18: 1090-1092.PubMed

24.

Berra E, Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J: HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in normoxia. EMBO J. 2003, 22: 4082-4090. 10.1093/emboj/cdg392.PubMedCentralCrossRefPubMed

25.

Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG: HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O₂ sensing. Science. 2001, 292: 464-468. 10.1126/science.1059817.CrossRefPubMed

26.

Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ: Targeting of HIF-α to the von Hippel–Lindau ubiquitylation complex by. Science. 2001, 292: 468-472. 10.1126/science.1059796.CrossRefPubMed

27.

Hewitson KS, McNeill LA, Riordan MV, Tian YM, Bullock AN, Welford RW, Elkins JM, Oldham NJ, Bhattacharya S, Gleadle JM, Ratcliffe PJ, Pugh CW, Schofield CJ: Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem. 2002, 277: 26351-26355. 10.1074/jbc.C200273200.CrossRefPubMed

28.

Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK: FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 2002, 16: 1466-1471. 10.1101/gad.991402.PubMedCentralCrossRefPubMed

29.

Cockman ME, Lancaster DE, Stolze IP, Hewitson KS, McDonough MA, Coleman ML, Coles CH, Yu X, Hay RT, Ley SC, Pugh CW, Oldham NJ, Masson N, Schofield CJ, Ratcliffe PJ: Post-translational hydroxylation of ankyrin repeats in IκB proteins by the hypoxia-inducible factor (HIF) asparaginyl hydroxylase, factor inhibiting HIF (FIH). Proc Natl Acad Sci USA. 2006, 103: 14767-14772. 10.1073/pnas.0606877103.PubMedCentralCrossRefPubMed

30.

Coleman ML, McDonough MA, Hewitson KS, Coles C, Mecinovic J, Edelmann M, Cook KM, Cockman ME, Lancaster DE, Kessler BM, Oldham NJ, Ratcliffe PJ, Schofield CJ: Asparaginyl hydroxylation of the Notch ankyrin repeat domain by factor inhibiting hypoxia-inducible factor. J Biol Chem. 2007, 282: 24027-24038. 10.1074/jbc.M704102200.CrossRefPubMed

31.

Zheng X, Linke S, Dias JM, Zheng X, Gradin K, Wallis TP, Hamilton BR, Gustafsson M, Ruas JL, Wilkins S, Bilton RL, Brismar K, Whitelaw ML, Pereira T, Gorman JJ, Ericson J, Peet DJ, Lendahl U, Poellinger L: Interaction with factor inhibiting HIF-1 defines an additional mode of cross-coupling between the Notch and hypoxia signaling pathways. Proc Natl Acad Sci USA. 2008, 105: 3368-3373. 10.1073/pnas.0711591105.PubMedCentralCrossRefPubMed

32.

Cramer T, Yamanishi Y, Clausen BE, Forster I, Pawlinski R, Mackman N, Haase VH, Jaenisch R, Corr M, Nizet V, Firestein GS, Gerber HP, Ferrara N, Johnson RS: HIF-1α is essential for myeloid cell-mediated inflammation. Cell. 2003, 112: 645-657. 10.1016/S0092-8674(03)00154-5.PubMedCentralCrossRefPubMed

33.

Hollander AP, Corke KP, Freemont AJ, Lewis CE: Expression of hypoxia-inducible factor 1α by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint. Arthritis Rheum. 2001, 44: 1540-1544. 10.1002/1529-0131(200107)44:7<1540::AID-ART277>3.0.CO;2-7.CrossRefPubMed

34.

Figueroa YG, Chan AK, Ibrahim R, Tang Y, Burow ME, Alam J, Scandurro AB, Beckman BS: NF-κB plays a key role in hypoxia-inducible factor-1-regulated erythropoietin gene expression. Exp Hematol. 2002, 30: 1419-1427. 10.1016/S0301-472X(02)00934-7.CrossRefPubMed

35.

Jung Y, Isaacs JS, Lee S, Trepel J, Liu ZG, Neckers L: Hypoxia-inducible factor induction by tumour necrosis factor in nor-moxic cells requires receptor-interacting protein-dependent nuclear factor κB activation. Biochem J. 2003, 370 (Pt 3): 1011-1017. 10.1042/BJ20021279.PubMedCentralCrossRefPubMed

36.

Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L: IL-1β-mediated up-regulation of HIF-1α via an NFκB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 2003, 17: 2115-2117.PubMed

37.

Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L: Microtubule disruption utilizes an NFκB-dependent pathway to stabilize HIF-1α protein. J Biol Chem. 2003, 278: 7445-7452. 10.1074/jbc.M209804200.CrossRefPubMed

38.

Belaiba RS, Bonello S, Zahringer C, Schmidt S, Hess J, Kietzmann T, Gorlach A: Hypoxia up-regulates hypoxia-inducible factor-1α transcription by involving phosphatidylinositol 3-kinase and nuclear factor κB in pulmonary artery smooth muscle cells. Mol Biol Cell. 2007, 18: 4691-4697. 10.1091/mbc.E07-04-0391.PubMedCentralCrossRefPubMed

39.

Bonello S, Zahringer C, BelAiba RS, Djordjevic T, Hess J, Michiels C, Kietzmann T, Gorlach A: Reactive oxygen species activate the HIF-1α promoter via a functional NFκB site. Arterioscler Thromb Vasc Biol. 2007, 27: 755-761. 10.1161/01.ATV.0000258979.92828.bc.CrossRefPubMed

40.

Frede S, Stockmann C, Freitag P, Fandrey J: Bacterial lipo-polysaccharide induces HIF-1 activation in human monocytes via p44/42 MAPK and NF-κB. Biochem J. 2006, 396: 517-527. 10.1042/BJ20051839.PubMedCentralCrossRefPubMed

41.

Kim J, Shao Y, Kim SY, Kim S, Song HK, Jeon JH, Suh HW, Chung JW, Yoon SR, Kim YS, Choi I: Hypoxia-induced IL-18 increases hypoxia-inducible factor-1α expression through a Rac1-dependent NF-κB pathway. Mol Biol Cell. 2008, 19: 433-444. 10.1091/mbc.E07-02-0182.PubMedCentralCrossRefPubMed

42.

Sun HL, Liu YN, Huang YT, Pan SL, Huang DY, Guh JH, Lee FY, Kuo SC, Teng CM: YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-κB signaling to HIF-1α accumulation during hypoxia. Oncogene. 2007, 26: 3941-3951. 10.1038/sj.onc.1210169.CrossRefPubMed

43.

Tacchini L, De Ponti C, Matteucci E, Follis R, Desiderio MA: Hepatocyte growth factor-activated NF-κB regulates HIF-1 activity and ODC expression, implicated in survival, differently in different carcinoma cell lines. Carcinogenesis. 2004, 25: 2089-2100. 10.1093/carcin/bgh227.CrossRefPubMed

44.

van Uden P, Kenneth NS, Rocha S: Regulation of hypoxia-inducible factor-1α by NF-κB. Biochem J. 2008, 412: 477-484. 10.1042/BJ20080476.PubMedCentralCrossRefPubMed

45.

Walmsley SR, Print C, Farahi N, Peyssonnaux C, Johnson RS, Cramer T, Sobolewski A, Condliffe AM, Cowburn AS, Johnson N, Chilvers ER: Hypoxia-induced neutrophil survival is mediated by HIF-1α-dependent NF-κB activity. J Exp Med. 2005, 201: 105-115. 10.1084/jem.20040624.PubMedCentralCrossRefPubMed

46.

Taylor CT: Interdependent roles for hypoxia inducible factor and nuclear factor-κB in hypoxic inflammation. J Physiol. 2008, 586 (Pt 17): 4055-4059. 10.1113/jphysiol.2008.157669.PubMedCentralCrossRefPubMed

47.

Gorlach A, Bonello S: The cross-talk between NF-κB and HIF-1: further evidence for a significant liaison. Biochem J. 2008, 412: e17-e19.CrossRefPubMed

48.

Murdoch C, Muthana M, Lewis CE: Hypoxia regulates macrophage functions in inflammation. J Immunol. 2005, 175: 6257-6263.CrossRefPubMed

49.

Taylor CT, Colgan SP: Hypoxia and gastrointestinal disease. J Mol Med. 2007, 85: 1295-1300. 10.1007/s00109-007-0277-z.CrossRefPubMed

50.

Distler O, Muller-Ladner U, Scholmerich J, Gay RE, Gay S: Rheumatoid arthritis: new molecular and cellular aspects. Med Klin (Munich). 1999, 94: 673-680.CrossRef

51.

FitzGerald O, Soden M, Yanni G, Robinson R, Bresnihan B: Morphometric analysis of blood vessels in synovial membranes obtained from clinically affected and unaffected knee joints of patients with rheumatoid arthritis. Ann Rheum Dis. 1991, 50: 792-796. 10.1136/ard.50.11.792.PubMedCentralCrossRefPubMed

52.

Paleolog EM: Angiogenesis in rheumatoid arthritis. Arthritis Res. 2002, 4 (Suppl 3): S81-S90. 10.1186/ar575.PubMedCentralCrossRefPubMed

53.

Bodamyali T, Stevens CR, Billingham ME, Ohta S, Blake DR: Influence of hypoxia in inflammatory synovitis. Ann Rheum Dis. 1998, 57: 703-710. 10.1136/ard.57.12.703.PubMedCentralCrossRefPubMed

54.

Thornton RD, Lane P, Borghaei RC, Pease EA, Caro J, Mochan E: Interleukin 1 induces hypoxia-inducible factor 1 in human gingival and synovial fibroblasts. Biochem J. 2000, 350 (Pt 1): 307-312. 10.1042/0264-6021:3500307.PubMedCentralCrossRefPubMed

55.

Makino Y, Nakamura H, Ikeda E, Ohnuma K, Yamauchi K, Yabe Y, Poellinger L, Okada Y, Morimoto C, Tanaka H: Hypoxia-inducible factor regulates survival of antigen receptor-driven T cells. J Immunol. 2003, 171: 6534-6540.CrossRefPubMed

56.

Ikeda E: Cellular response to tissue hypoxia and its involvement in disease progression. Pathol Int. 2005, 55: 603-610. 10.1111/j.1440-1827.2005.01877.x.CrossRefPubMed

57.

Oikawa M, Abe M, Kurosawa H, Hida W, Shirato K, Sato Y: Hypoxia induces transcription factor ETS-1 via the activity of hypoxia-inducible factor-1. Biochem Biophys Res Commun. 2001, 289: 39-43. 10.1006/bbrc.2001.5927.CrossRefPubMed

58.

Wernert N, Gilles F, Fafeur V, Bouali F, Raes MB, Pyke C, Dupressoir T, Seitz G, Vandenbunder B, Stehelin D: Stromal expression of c-Ets1 transcription factor correlates with tumor invasion. Cancer Res. 1994, 54: 5683-5688.PubMed

59.

Hitchon CA, El-Gabalawy HS: Oxidation in rheumatoid arthritis. Arthritis Res Ther. 2004, 6: 265-278. 10.1186/ar1447.PubMedCentralCrossRefPubMed

60.

Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, Berse B, Dvorak HF: Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med. 1994, 180: 1141-1146. 10.1084/jem.180.3.1141.CrossRefPubMed

61.

Rosenberger C, Solovan C, Rosenberger AD, Jinping L, Treudler R, Frei U, Eckardt KU, Brown LF: Upregulation of hypoxia-inducible factors in normal and psoriatic skin. J Invest Dermatol. 2007, 127: 2445-2452. 10.1038/sj.jid.5700874.CrossRefPubMed

62.

Chen LW, Egan L, Li ZW, Greten FR, Kagnoff MF, Karin M: The two faces of IKK and NF-κB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med. 2003, 9: 575-581. 10.1038/nm849.CrossRefPubMed

63.

Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M: IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004, 118: 285-296. 10.1016/j.cell.2004.07.013.CrossRefPubMed

64.

Karhausen J, Furuta GT, Tomaszewski JE, Johnson RS, Colgan SP, Haase VH: Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest. 2004, 114: 1098-1106.PubMedCentralCrossRefPubMed

65.

Elvidge GP, Glenny L, Appelhoff RJ, Ratcliffe PJ, Ragoussis J, Gleadle JM: Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1α, HIF-2α, and other pathways. J Biol Chem. 2006, 281: 15215-15226. 10.1074/jbc.M511408200.CrossRefPubMed

66.

Cummins EP, Seeballuck F, Keely SJ, Mangan NE, Callanan JJ, Fallon PG, Taylor CT: The hydroxylase inhibitor dimethyloxalyl-glycine is protective in a murine model of colitis. Gastroenterology. 2008, 134: 156-165. 10.1053/j.gastro.2007.10.012.CrossRefPubMed

67.

Assi K, Pillai R, Gomez-Munoz A, Owen D, Salh B: The specific JNK inhibitor SP600125 targets tumour necrosis factor-α production and epithelial cell apoptosis in acute murine colitis. Immunology. 2006, 118: 112-121. 10.1111/j.1365-2567.2006.02349.x.PubMedCentralCrossRefPubMed

68.

Lugering A, Lebiedz P, Koch S, Kucharzik T: Apoptosis as a therapeutic tool in IBD?. Ann N Y Acad Sci. 2006, 1072: 62-77. 10.1196/annals.1326.013.CrossRefPubMed

69.

Robinson A, Keely S, Karhausen J, Gerich ME, Furuta GT, Colgan SP: Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology. 2008, 134: 145-155. 10.1053/j.gastro.2007.09.033.PubMedCentralCrossRefPubMed

70.

Shah YM, Ito S, Morimura K, Chen C, Yim SH, Haase VH, Gonzalez FJ: Hypoxia-inducible factor augments experimental colitis through an MIF-dependent inflammatory signaling cascade. Gastroenterology. 2008, 134: 2036-2048. 10.1053/j.gastro.2008.03.009.PubMedCentralCrossRefPubMed

71.

Kasiganesan H, Sridharan V, Wright G: Prolyl hydroxylase inhibitor treatment confers whole-animal hypoxia tolerance. Acta Physiol (Oxf). 2007, 190: 163-169. 10.1111/j.1748-1716.2007.01676.x.CrossRef

72.

Nangaku M, Izuhara Y, Takizawa S, Yamashita T, Fujii-Kuriyama Y, Ohneda O, Yamamoto M, van Ypersele de Strihou C, Hirayama N, Miyata T: A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia. Arterioscler Thromb Vasc Biol. 2007, 27: 2548-2554. 10.1161/ATVBAHA.107.148551.CrossRefPubMed

73.

Natarajan R, Salloum FN, Fisher BJ, Ownby ED, Kukreja RC, Fowler AA: Activation of hypoxia-inducible factor-1 via prolyl-4 hydoxylase-2 gene silencing attenuates acute inflammatory responses in postischemic myocardium. Am J Physiol Heart Circ Physiol. 2007, 293: H1571-H1580. 10.1152/ajpheart.00291.2007.CrossRefPubMed

74.

Bernhardt WM, Campean V, Kany S, Jurgensen JS, Weidemann A, Warnecke C, Arend M, Klaus S, Gunzler V, Amann K, Willam C, Wiesener MS, Eckardt KU: Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure. J Am Soc Nephrol. 2006, 17: 1970-1978. 10.1681/ASN.2005121302.CrossRefPubMed

75.

Hill P, Shukla D, Tran MG, Aragones J, Cook HT, Carmeliet P, Maxwell PH: Inhibition of hypoxia inducible factor hydroxylases protects against renal ischemia-reperfusion injury. J Am Soc Nephrol. 2008, 19: 39-46. 10.1681/ASN.2006090998.PubMedCentralCrossRefPubMed

76.

Rosenberger C, Rosen S, Shina A, Frei U, Eckardt KU, Flippin LA, Arend M, Klaus SJ, Heyman SN: Activation of hypoxia inducible factors (HIF) ameliorates hypoxic distal tubular injury in the isolated perfused rat kidney. Nephrol Dial Transplant. 2008, 28: 831-839.

77.

Bishop T, Gallagher D, Pascual A, Lygate CA, de Bono JP, Nicholls LG, Ortega-Saenz P, Oster H, Wijeyekoon B, Sutherland AI, Grosfeld A, Aragones J, Schneider M, van Geyte K, Teixeira D, Diez-Juan A, Lopez-Barneo J, Channon KM, Maxwell PH, Pugh CW, Davies AM, Carmeliet P, Ratcliffe PJ: Abnormal sympathoadrenal development and systemic hypotension in PHD3^-/- mice. Mol Cell Biol. 2008, 28: 3386-3400. 10.1128/MCB.02041-07.PubMedCentralCrossRefPubMed

78.

Aragones J, Schneider M, Van Geyte K, Fraisl P, Dresselaers T, Mazzone M, Dirkx R, Zacchigna S, Lemieux H, Jeoung NH, Lambrechts D, Bishop T, Lafuste P, Diez-Juan A, Harten SK, Van Noten P, De Bock K, Willam C, Tjwa M, Grosfeld A, Navet R, Moons L, Vandendriessche T, Deroose C, Wijeyekoon B, Nuyts J, Jordan B, Silasi-Mansat R, Lupu F, Dewerchin M, Pugh C, Salmon P, Mortelmans L, Gallez B, Gorus F, Buyse J, Sluse F, Harris RA, Gnaiger E, Hespel P, Van Hecke P, Schuit F, Van Veldhoven P, Ratcliffe P, Baes M, Maxwell P, Carmeliet P: Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet. 2008, 40: 170-180. 10.1038/ng.2007.62.CrossRefPubMed

79.

Takeda K, Ho VC, Takeda H, Duan LJ, Nagy A, Fong GH: Placental but not heart defects are associated with elevated hypoxia-inducible factor α levels in mice lacking prolyl hydroxylase domain protein 2. Mol Cell Biol. 2006, 26: 8336-8346. 10.1128/MCB.00425-06.PubMedCentralCrossRefPubMed

80.

Holtmann MH, Neurath MF: Differential TNF-signaling in chronic inflammatory disorders. Curr Mol Med. 2004, 4: 439-444. 10.2174/1566524043360636.CrossRefPubMed

81.

Pallone F, Monteleone G: Mechanisms of tissue damage in inflammatory bowel disease. Curr Opin Gastroenterol. 2001, 17: 307-312. 10.1097/00001574-200107000-00002.CrossRefPubMed

Titel: Hypoxia. Regulation of NFκB signalling during inflammation: the role of hydroxylases
verfasst von: Kathryn M Oliver
Cormac T Taylor
Eoin P Cummins
Publikationsdatum: 01.02.2009
Verlag: BioMed Central
Erschienen in: Arthritis Research & Therapy / Ausgabe 1/2009
Elektronische ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar2575

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2009

Developments in the scientific and clinical understanding of the spondyloarthritides

Dissection of a locus on mouse chromosome 5 reveals arthritis promoting and inhibitory genes

Distinct synovial immunopathology in Behçet disease and psoriatic arthritis

Interactions among type I and type II interferon, tumor necrosis factor, and β-estradiol in the regulation of immune response-related gene expressions in systemic lupus erythematosus

Transcription profiling of rheumatic diseases